Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset
    A study of the  victims with effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset showed a decrease in rehabilitation costs of $1.4 million and nursing home costs of…  
  • A blood thinning drug was found to reduce the risk of heart attack, stroke, and cardiovascular disease by 20% in patients with acute coronary syndrome when given in addition to…  
  • Compared to predicted levels in the absence of drug therapy, there were 9% fewer deaths from major cardiovascular disease in 2001 and 38% and 25% fewer hospital discharges for stroke…  
  • Aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins, when taken in combination, have been estimated to reduce the relative risk of coronary heart disease mortality by 80%, compared with a placebo.  
  • Glycoprotein inhibitors have been shown to reduce the risk of death, a second heart attack, or the need for revascularization by 48% to 52% in patients who have suffered a…